FT576 in Subjects With Multiple Myeloma
Completed · Phase 1
Conditions studied: Multiple Myeloma, Myeloma
In brief
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Key facts
- Study ID
- NCT05182073
- Run by
- Fate Therapeutics
- People needed
- 31
- Starts
- 2021-11-10
- Expected to finish
- 2024-10-18
- Last updated by the study team
- 2025-12-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- City of Hope — Duarte, California, United States
- Scri-Cbci — Denver, Colorado, United States
- Medical Oncology Hematology Consultants — Newark, Delaware, United States
- Indiana University — Indianapolis, Indiana, United States
- University of Minnesota — Saint Paul, Minnesota, United States
- Washington University — St Louis, Missouri, United States
- Roswell Park — Buffalo, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Oncology Hematology Care, Inc — Cincinnati, Ohio, United States
- Tennessee Oncology - Nashville — Nashville, Tennessee, United States
- Texas Oncology-Medical City Dallas — Dallas, Texas, United States
- Virginia Oncology Associates — Norfolk, Virginia, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.